MX2023001483A - Compuestos inmunogenicos. - Google Patents
Compuestos inmunogenicos.Info
- Publication number
- MX2023001483A MX2023001483A MX2023001483A MX2023001483A MX2023001483A MX 2023001483 A MX2023001483 A MX 2023001483A MX 2023001483 A MX2023001483 A MX 2023001483A MX 2023001483 A MX2023001483 A MX 2023001483A MX 2023001483 A MX2023001483 A MX 2023001483A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- defined above
- present
- immunogenic compounds
- peptide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 1
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un péptido antigénico comprende la estructura X1-X2-X3-X4-X5-X6-X7-P-X9-X10-X11-X12 y se deriva de los aminoácidos 113-124 de la alfa sinucleína. De acuerdo con la estructura: P es prolina; X1 es L, K, A o S, en donde L es leucina, K es lisina, A es alanina y S es serina; X2 es E o S, en donde E y S son como se definieron anteriormente; X3 es D, E, K, N, A o S, en donde N es asparagina, D es ácido aspártico y D, E, K, A y S son como se definieron anteriormente; X4 es M, A, S, L o K, en donde M es metionina y A, S, L y K son como se definieron anteriormente; X5 es P o A como se definió anteriormente; X6 es V, A o S, en donde V es valina y A y S son como se definieron anteriormente; X7 es D o S como se definió anteriormente; X9 es D o A como se definió anteriormente; X10 es N, S o A, en donde N, S y A son como se definieron anteriormente; X11 es E, A o S, en donde E, A y S son como se definieron anteriormente; X12 está presente o no y, si está presente, es A, K, V, S o G, en donde G es glicina y A, K, V y S son como se definieron anteriormente. La estructura comprende al menos una mutación en comparación con la secuencia L-E-D-M-P-V-D-P-D-N-E-A de tipo salvaje. El péptido no comprende el dipéptido Y-E inmediatamente después de X12, en donde Y es tirosina y E es como se definió anteriormente. Los péptidos se conjugan con un portador adecuado y son útiles en el tratamiento de sinucleinopatías.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20189425 | 2020-08-04 | ||
| PCT/EP2021/071778 WO2022029181A1 (en) | 2020-08-04 | 2021-08-04 | Immunogenic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001483A true MX2023001483A (es) | 2023-03-08 |
Family
ID=72178339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001483A MX2023001483A (es) | 2020-08-04 | 2021-08-04 | Compuestos inmunogenicos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230287050A1 (es) |
| EP (1) | EP4192493A1 (es) |
| JP (1) | JP2023536497A (es) |
| KR (1) | KR20230044524A (es) |
| CN (1) | CN116261464A (es) |
| AU (1) | AU2021322080A1 (es) |
| CA (1) | CA3185563A1 (es) |
| IL (1) | IL300364A (es) |
| MX (1) | MX2023001483A (es) |
| WO (1) | WO2022029181A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024009485A (es) * | 2022-02-09 | 2024-08-14 | Ac Immune Sa | Vacunas terapeuticas anti-alfa-sinucleina. |
| WO2024156908A1 (en) | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Liposomal construct |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4820291B2 (ja) | 2003-05-19 | 2011-11-24 | エラン ファーマシューティカルズ，インコーポレイテッド | レヴィー小体病におけるαシヌクレインの切断断片 |
| WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| WO2017076873A1 (en) | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| SG11201912195TA (en) * | 2017-06-16 | 2020-01-30 | United Neuroscience | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies |
| CA3150726A1 (en) * | 2019-09-20 | 2021-03-25 | Jing Guo | Anti-alpha-synuclein antibodies and methods of use thereof |
-
2021
- 2021-08-04 KR KR1020237007745A patent/KR20230044524A/ko active Search and Examination
- 2021-08-04 AU AU2021322080A patent/AU2021322080A1/en active Pending
- 2021-08-04 CA CA3185563A patent/CA3185563A1/en active Pending
- 2021-08-04 CN CN202180050068.9A patent/CN116261464A/zh active Pending
- 2021-08-04 IL IL300364A patent/IL300364A/en unknown
- 2021-08-04 MX MX2023001483A patent/MX2023001483A/es unknown
- 2021-08-04 WO PCT/EP2021/071778 patent/WO2022029181A1/en active Application Filing
- 2021-08-04 US US18/014,846 patent/US20230287050A1/en active Pending
- 2021-08-04 EP EP21758636.1A patent/EP4192493A1/en active Pending
- 2021-08-04 JP JP2023507480A patent/JP2023536497A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4192493A1 (en) | 2023-06-14 |
| CN116261464A (zh) | 2023-06-13 |
| US20230287050A1 (en) | 2023-09-14 |
| WO2022029181A1 (en) | 2022-02-10 |
| IL300364A (en) | 2023-04-01 |
| JP2023536497A (ja) | 2023-08-25 |
| KR20230044524A (ko) | 2023-04-04 |
| CA3185563A1 (en) | 2022-02-10 |
| AU2021322080A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001483A (es) | Compuestos inmunogenicos. | |
| Toniolo et al. | Intramolecularly hydrogen-bonded peptide conformation | |
| Chang et al. | Solid‐Phase Peptide Synthesis Using Mild Base Cleavage of Nαfluorenylmethyloxycarbonylamino Acids, Exemplified By a Synthesis of Dihydrosomatostatin | |
| Fukase et al. | Total synthesis of peptide antibiotic nisin | |
| US3929758A (en) | Cyclization of cysteine-containing peptides | |
| IL152625A (en) | Synthetic but not amyloidogenic immunogenic peptides equivalent to amyloid b to elicit an immune response to amyloid b and amyloid deposits | |
| ES2044841T3 (es) | Procedimiento de preparacion de peptidos sinteticos con actividad de interleuquin 1 humana. | |
| KR850007801A (ko) | 폴리펩타이드의 제조방법 | |
| CA2155004A1 (en) | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same | |
| DE68916900D1 (de) | Erregung der chemotaxe durch chemotaktische peptide. | |
| HK1071909A1 (en) | Gene and polypeptide sequences | |
| DE69325178D1 (de) | Durch peptidylketon aktivierte inhibitoren, die natürliche und nicht-natürliche peptidsequenzen enthalten | |
| US20120108748A1 (en) | Solid phase peptide synthesis of peptide alcohols | |
| ZA200604772B (en) | Production of diphtheria toxin | |
| CN104593317B (zh) | 一种用于细胞培养基的大豆活性肽添加剂 | |
| MX2023005771A (es) | Tetrapeptido y composiciones que comprenden tetrapeptidos. | |
| Hirano et al. | Racemization of amino acid residues in proteins during roasting | |
| EA201100459A1 (ru) | Композиции, включающие интерлейкин-1 и пептиды | |
| SG63621A1 (en) | Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines | |
| US9598714B2 (en) | Side-chain protected oligopeptide fragment condensation using subtilisins in organic solvents | |
| MX2024009485A (es) | Vacunas terapeuticas anti-alfa-sinucleina. | |
| FR2446292B1 (es) | ||
| US20180215784A1 (en) | Method for preparation of n-acyl peptides, polypeptides and proteins | |
| ES2072422T3 (es) | Procedimiento para la produccion de peptidos amidados en alfa en el terminal c. | |
| Chiou et al. | Biochemical comparison of γ-crystallins from duck and frog eye lenses |